Clinical trials: Inhibition
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients.
- Conditions
- Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
- Trial name
- NCT03423628
- Testing
- Radiation Therapy, AZD1390
- Where
- 11 sites in United States, Japan and 1 more
- Volunteers
- 159 people
- Sponsor
- AstraZeneca
Lung Cancer
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT02917993
- Testing
- Itacitinib, Osimertinib
- Where
- 31 sites in United States, South Korea and 2 more
- Volunteers
- 59 people
- Sponsor
- Incyte Corporation
Bioequivalence, Healthy Volunteers
A Study to Learn if There is a Difference in the Blood Levels of Acetylsalicylic Acid When Taken as Different Chewable Tablets on an Empty Stomach by Healthy Participants
In this study, researchers want to learn if 2 different forms of acetylsalicylic acid (ASA) chewable tablets will have the same effect in the body.
- Conditions
- Bioequivalence, Healthy Volunteers, Platelet Aggregation Inhibition
- Trial name
- NCT06655194
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477), Acetylsalicylic Acid (BAYE004465, UI1615160)
- Where
- Mexico
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Bayer
Arthrogenic Muscle Inhibition, Arthrogenic Muscle Inhibitions
Evaluation of the Efficacy of the ALLYANE Procedure in the Treatment of Central Motor Inhibition
The goal of this clinical study is to determine the effectiveness of restoring muscle strength in the management of motor inhibition when complemented by the ALLYANE process (neuro-motor reprogramming) compared to a standard…
- Trial name
- NCT06774157
- Testing
- A session combining motor imagery and listening to low frequency sounds, Standard management - Control group
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Allyane
Subjects With Hyperlipidemia, Dyslipidemia
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
A study to assess the effects of proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibition on the arterial wall inflammation in patients with elevated lipoprotein(a).
- Trial name
- ANITSCHKOW (NCT02729025)
- Testing
- Evolocumab
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 129 people
- Sponsor
- Amgen
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia
The study is divided into 2 parts. The first part of the study will be double-blinded and will last for 24 weeks. During this time, participants will be randomized in a ratio of 2:1 to receive either evolocumab once monthly (QM)…
- Trial name
- NCT02833844
- Testing
- Evolocumab
- Where
- 78 sites in United States, Australia and 13 more
- Volunteers
- 467 people
- Sponsor
- Amgen
Pre-menopausal Breast Cancer, PI3K Pathway Inhibition
A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer
Based on the evidence acquired in the post-menopausal setting with everolimus and on pre-clinical evidences supporting the investigation of PI3K inhibitors, such as alpelisib and buparlisib, in combination with endocrine therapy…
- Trial name
- B-YOND (NCT02058381)
- Testing
- alpelisib (BYL719), buparlisib (BKM120)
- Where
- 15 sites in Hong Kong, South Korea and 2 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Sickle Cell Disease
A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
The purpose of this study was to evaluate the safety and tolerability, and the pharmacokinetic and biologic activity of INCB059872 in participants with sickle cell disease.
- Trial name
- NCT03132324
- Testing
- INCB059872
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Incyte Corporation
Non-tuberculous Mycobacterial Diseases, Tuberculosis
Safety And Efficacy Of Rifabutin In HIV Patients
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Conditions
- Non-tuberculous Mycobacterial Diseases, Tuberculosis, Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections
- Trial name
- NCT00810446
- Testing
- rifabutin
- Volunteers
- 72 people
- Sponsor
- Pfizer
Inhibition of Plaque Formation (by Gingivitis-Index ≤1.5)
Study to Assess the Inhibition of Plaque Formation in Subjects With a Gingival Index ≤1.5
The objective of the study is to demonstrate the superiority of 0.1% octenidine mouthwash (Octenidin Mundspüllösung, OML) to placebo (PLAC) in the inhibition of plaque formation.
- Trial name
- NCT03322124
- Testing
- Octenidinedihydrochlorid
- Where
- 3 sites in Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Schülke & Mayr GmbH
Inhibition of Plaque Formation (by Gingivitis-Index ≤1.5)
Study to Assess the Inhibition of Plaque Formation in Subjects With a Gingival Index ≤1.5
The objective of the study is to demonstrate the superiority of 0.1% octenidine mouthwash (Octenidin Mundspüllösung, OML) to placebo (PLAC) in the inhibition of plaque formation.
- Trial name
- NCT03378401
- Testing
- Octenidinedihydrochlorid
- Where
- 3 sites in Austria, Germany
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Schülke & Mayr GmbH
Cholesterol Absorption Inhibition
Cholesterol Absorption Inhibition Study
Rationale: Consuming Plant Sterols (PS) fortified foods is widely accepted as easy to apply, life-style change to combat modestly elevated plasma cholesterol concentrations.
- Trial name
- CASTELL (NCT01138787)
- Testing
- Reference spread, Test spread
- Where
- Netherlands
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Pharmacokinetics, Inhibition Enzyme
Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1
The purpose of the study is: to determine absolute bioavailability, input rates, distribution volume, renal and intestinal excretion of trospium in subjects with wild-type of SLC22A1 rs72552763 and rs12208357 and in subjects with…
- Conditions
- Pharmacokinetics, Inhibition Enzyme, Drug Interaction Potentiation
- Trial name
- NCT03011463
- Testing
- intravenous infusion of 2 mg trospium chloride, oral administration of 30 mg trospium chloride, oral administration of 300 mg ranitidine
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Dr. R. Pfleger Chemische Fabrik GmbH
FGFR Inhibition, Pharmacokinetics, Biomarkers, ER+ Breast Cancer
Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients
The purpose of this study is to assess the safety and effectiveness of AZD4547 in combination with fulvestrant vs. fulvestrant alone in ER+ breast cancer patients with FGFR1 polysomy (FISH4/5) or gene amplification (FISH 6)
- Trial name
- GLOW (NCT01202591)
- Testing
- AZD4547, Exemestane, Fulvestrant
- Where
- 21 sites in Belgium, Czechia and 6 more
- Volunteers
- 127 people
- Sponsor
- AstraZeneca
Contraception, Ovulation Inhibition
Inhibition of Ovulation, Patch, Ethinylestradiol and Gestodene
Investigation of two transdermal hormone patch formulations for contraception regarding inhibition of ovulation over a period of 3 treatment cycles in healthy young female volunteers
- Trial name
- NCT00729404
- Testing
- Ethinylestradiol/Gestodene (BAY86-5016)
- Where
- 3 sites in Germany
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception, Ovulation Inhibition
Inhibition of Ovulation and Pharmacokinetics of Transdermal Ethinylestradiol (EE) and Gestodene (GSD)
Investigation of two transdermal hormone patch formulations for contraception regarding inhibition of ovulation over a period of 3 treatment cycles in healthy young female volunteers
- Trial name
- NCT00915915
- Testing
- Ethinylestradiol/Gestodene (BAY86-5016)
- Where
- 2 sites in Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Bayer
Inhibition on Platelet Aggregation
Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets
Study to see if platelet transfusion stop or lessen the effect of the drug on platelets
- Trial name
- NCT01744288
- Testing
- Ticagrelor, Clopidogrel, ASA
- Where
- United States
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Contraception, Ovulation Inhibition
Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ
The purpose of this study is to determine whether the study drug is safe and effective.
- Conditions
- Contraception, Ovulation Inhibition, Contraceptives, Oral
- Trial name
- NCT00567164
- Testing
- EE20/DRSP (BAY86-5300), EE20/DRSP (YAZ, BAY86-5300)
- Where
- 85 sites in United States
- Volunteers
- 1,887 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception, Ovulation Inhibition
Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium
Investigation of the bioequivalence (BE) of Estradiol Valerate (EV) after administration of one film-coated tablet containing 3 mg Estradiol Valerate and 0.451 mg Levomefolate calcium as compared to one film-coated tablet…
- Trial name
- NCT01031355
- Testing
- Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078), Estradiol Valerate (EV) (BAY86-4980), Levomefolate Calcium (BAY86-7660)
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Bayer
HDL, Drug Safety
Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)
Phase 1 Study :Safety, Immunogenicity and Dose response of ATH03, a new vaccine against the cholesterol ester transfer protein (CETP), in healthy male subjects with high density lipoprotein cholesterol (HDLc) blood concentrations…
- Trial name
- NCT01284582
- Testing
- ATH03
- Where
- Austria
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Affiris AG